VistaGen Therapeutics Reports Fiscal Year 2022 First Quarter Financial Results and Provides Corporate Update
12 août 2021 16h25 HE
|
VistaGen Therapeutics, Inc.
PALISADE Phase 3 Program to evaluate PH94B for rapid-onset acute treatment of anxiety in adults with social anxiety disorder (SAD) progressing on plan Additional potential...
VistaGen Therapeutics to Report Fiscal Year 2022 First Quarter Financial Results and Host Conference Call and Webcast on August 12, 2021
09 août 2021 16h05 HE
|
VistaGen Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Aug. 09, 2021 (GLOBE NEWSWIRE) -- VistaGen Therapeutics, Inc. (NASDAQ: VTGN), a biopharmaceutical company committed to developing a new generation of medicines with the...
VistaGen Therapeutics to Participate in Canaccord Genuity 41st Annual Growth Conference
02 août 2021 08h00 HE
|
VistaGen Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Aug. 02, 2021 (GLOBE NEWSWIRE) -- VistaGen Therapeutics (NASDAQ: VTGN), a biopharmaceutical company committed to developing a new generation of medicines with the...
VistaGen Therapeutics Announces Appointment of Maggie FitzPatrick to its Board of Directors
22 juil. 2021 08h00 HE
|
VistaGen Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., July 22, 2021 (GLOBE NEWSWIRE) -- VistaGen Therapeutics, Inc. (NASDAQ: VTGN), a biopharmaceutical company committed to developing a new generation of medicines with the...
VistaGen Therapeutics to Participate in William Blair Biotech Focus Conference 2021
09 juil. 2021 08h30 HE
|
VistaGen Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., July 09, 2021 (GLOBE NEWSWIRE) -- VistaGen Therapeutics (NASDAQ: VTGN), a biopharmaceutical company committed to developing a new generation of medicines with the...
VistaGen Therapeutics Announces Appointment of Mary L. Rotunno to its Board of Directors
07 juil. 2021 08h30 HE
|
VistaGen Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., July 07, 2021 (GLOBE NEWSWIRE) -- VistaGen Therapeutics, Inc. (NASDAQ: VTGN), a biopharmaceutical company committed to developing a new generation of medicines with the...
VistaGen Therapeutics Reports Fiscal Year 2021 Financial Results and Provides Corporate Update
29 juin 2021 16h15 HE
|
VistaGen Therapeutics, Inc.
PALISADE-1 Phase 3 trial underway to evaluate PH94B for rapid-onset acute treatment of anxiety in adults with social anxiety disorder (SAD) Management to host corporate update conference call and...
VistaGen Therapeutics to Report 2021 Fiscal Year End Financial Results, Provide a Business Update and Host Conference Call and Webcast June 29, 2021
25 juin 2021 08h00 HE
|
VistaGen Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., June 25, 2021 (GLOBE NEWSWIRE) -- VistaGen Therapeutics, Inc. (NASDAQ: VTGN), a biopharmaceutical company committed to developing a new generation of medicines with the...
VistaGen Therapeutics Set to Join the Russell 2000® Index
16 juin 2021 08h00 HE
|
VistaGen Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., June 16, 2021 (GLOBE NEWSWIRE) -- VistaGen Therapeutics, Inc. (NASDAQ: VTGN), a biopharmaceutical company committed to developing and commercializing a new generation of...
VistaGen Therapeutics Initiates PALISADE Phase 3 Trial of PH94B in Social Anxiety Disorder
26 mai 2021 08h00 HE
|
VistaGen Therapeutics, Inc.
PALISADE Phase 3 Program focused on acute treatment of anxiety in adults with Social Anxiety Disorder FDA Fast Track designation granted Topline results anticipated in mid-2022 SOUTH SAN FRANCISCO,...